HC Wainwright Issues Pessimistic Outlook for Cibus Earnings

Cibus, Inc. (NASDAQ:CBUS) – Stock analysts at HC Wainwright dropped their Q4 2024 EPS estimates for Cibus in a research note issued on Monday, November 11th. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings of ($1.00) per share for the quarter, down from their prior estimate of ($0.96). HC Wainwright currently has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Cibus’ current full-year earnings is ($3.50) per share. HC Wainwright also issued estimates for Cibus’ FY2025 earnings at ($3.38) EPS, FY2026 earnings at ($3.16) EPS, FY2027 earnings at ($2.39) EPS and FY2028 earnings at ($1.05) EPS.

Several other analysts have also recently weighed in on the stock. Canaccord Genuity Group raised shares of Cibus to a “strong-buy” rating in a research note on Friday, July 19th. Alliance Global Partners dropped their target price on shares of Cibus from $25.00 to $23.50 and set a “buy” rating on the stock in a report on Tuesday, September 24th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 price objective on shares of Cibus in a report on Tuesday, October 22nd.

Cibus Stock Performance

NASDAQ CBUS opened at $4.78 on Wednesday. Cibus has a fifty-two week low of $2.86 and a fifty-two week high of $23.18. The stock has a market cap of $126.46 million, a PE ratio of -0.21 and a beta of 1.79. The firm’s fifty day moving average price is $4.03 and its two-hundred day moving average price is $8.58.

Institutional Investors Weigh In On Cibus

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC bought a new stake in Cibus in the 3rd quarter worth about $33,000. FineMark National Bank & Trust grew its position in Cibus by 24.3% in the 2nd quarter. FineMark National Bank & Trust now owns 20,488 shares of the company’s stock worth $202,000 after purchasing an additional 4,000 shares in the last quarter. Squarepoint Ops LLC bought a new stake in Cibus in the 2nd quarter worth about $214,000. Rhumbline Advisers bought a new stake in Cibus in the 2nd quarter worth about $221,000. Finally, Swan Global Investments LLC bought a new stake in Cibus in the 3rd quarter worth about $115,000. Institutional investors and hedge funds own 33.81% of the company’s stock.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.